Valuation: Laboratorio Reig Jofre SA

Market Cap 217M 0 247M 201M 185M 348M 23.79B 352M 2.39B 937M 11.66B 927M 907M 40.26B P/E 2026 *
13.3x
P/E 2027 * 22.2x
Enterprise Value 301M 0 344M 279M 257M 484M 33.1B 490M 3.33B 1.3B 16.22B 1.29B 1.26B 56.01B EV / Sales 2026 *
0.83x
EV / Sales 2027 * 0.75x
Free-Float
20.57%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 58 2005-12-31
Director of Finance/CFO - 2023-12-19
Chief Tech/Sci/R&D Officer - 2002-12-31
Director TitleAgeSince
Chairman - 2014-12-30
Director/Board Member 58 2014-12-30
Director/Board Member - 2017-11-06
Change 5-day change 1-year change 3-year change Capi.($)
+2.41%-.--% - - 247M
+2.49%+1.98%+54.22%+154.40% 1,048B
+0.72%-1.28%+52.48%+47.25% 603B
+1.07%+4.62%+38.54%+78.17% 452B
+0.45%+1.36%+31.72%+22.38% 327B
+0.73%+3.51%+37.04%+39.07% 283B
+1.80%+1.05%+22.66%+17.79% 259B
-0.39%-2.41%-23.90%-41.35% 219B
+0.57%+3.09%+23.78%+55.97% 198B
-2.20%+0.18%+20.32%+61.56% 162B
Average +0.77%+1.74%+28.54%+48.36% 394.63B
Weighted average by Cap. +1.15%+1.69%+38.13%+73.40%

Financials

2026 *2027 *
Net sales 365M 0 416M 338M 311M 587M 40.09B 594M 4.04B 1.58B 19.65B 1.56B 1.53B 67.85B 392M 0 447M 363M 334M 630M 43.06B 638M 4.33B 1.7B 21.1B 1.68B 1.64B 72.87B
Net income 16.7M 0 19.05M 15.47M 14.24M 26.86M 1.83B 27.18M 185M 72.27M 899M 71.52M 69.98M 3.11B 9.5M 0 10.84M 8.8M 8.1M 15.28M 1.04B 15.46M 105M 41.11M 512M 40.69M 39.81M 1.77B
Net Debt 84.7M 0 96.63M 78.48M 72.23M 136M 9.31B 138M 937M 367M 4.56B 363M 355M 15.75B 78.7M 0 89.79M 72.92M 67.12M 127M 8.65B 128M 870M 341M 4.24B 337M 330M 14.63B
Logo Laboratorio Reig Jofre SA
Laboratorio Reig Jofre SA, formerly Natraceutical SA, is a Spain-based company primarily engaged in the research, development, manufacturing and marketing of drugs. The Company’s activities are divided into four business divisions: Industrial Services, providing production services for third parties; Pharma, selling own pharmaceuticals under a range of brands, such as Reig Jofre, Medea, Orravan, Bioglan and Sala; Reaserch and Development (R&D) and Regulatory, including the development of indications for existing molecules, as well as generics and molecular diagnostics, among others; and Biotech, offering biopharmaceutical support services, such as analytical and process development, quality control and assurance, as well as stability studies. The Company also provides nutritional cosmetics, and food supplements, among others. It operates worldwide in Europe, Africa, the Americas, Australia and Asia through a number of subsidiaries, including Chiesi Espana SA and Oryzon Genomics SA.
Employees
-
Trader
-
Investor
Global
-
Quality
ESG MSCI
-